Skip to main content
Premium Trial:

Request an Annual Quote

SyStemix Uses Neomorphic Software to Identify Genes

Premium

BERKELEY, Calif.--Neomorphic Software has closed a deal with SyStemix, a Novartis company. Neomorphic's hidden-Markov-model-based technology will be used to find novel genes in SyStemix's proprietary sequences that are unable to be classified using existing sequence analysis tools. Martin Reese, Neomorphic's chief scientific officer, said the deal would give Neomorphic "the opportunity to work closely with geneticists to verify and optimize this technology towards the discovery of new genes."

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.